Overview

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Status:
Recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).

Phase:

Phase 1

Details

Lead Sponsor:

University of Alabama at Birmingham
University of Kansas Medical Center

Collaborators:

In8bio Inc.
Incysus

Treatments:

Cyclophosphamide